Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana.
Humans
Carbapenems
/ pharmacology
Escherichia coli
Prevalence
Ghana
/ epidemiology
beta-Lactamases
/ genetics
Enterobacteriaceae
/ genetics
Anti-Bacterial Agents
/ pharmacology
Klebsiella pneumoniae
/ genetics
Carbapenem-Resistant Enterobacteriaceae
/ genetics
Microbial Sensitivity Tests
Hospitals, Teaching
Serratia
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
08
2022
accepted:
18
09
2023
medline:
2
11
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Carbapenem-resistant Enterobacteriaceae (CRE) and Extended-spectrum beta-lactamase (ESBL) production among Gram-negative Enterobacteriaceae is an increasing global challenge due to the high morbidity and mortality associated with their infections, especially in developing countries where there are little antibiotic treatment options. Despite these challenges, few studies in Ghana have described the burden of CRE. Therefore, this study aimed to determine the prevalence of carbapenem-resistant Enterobacteriaceae isolated from patients at the Cape Coast Teaching Hospital (CCTH) in the Central region of Ghana. Enterobacteriaceae isolates were collected from April to July 2019 at the bacteriology unit of CCTH using a consecutive sampling method. Isolates were identified by standard microbiological techniques and confirmed using API 20E. Kirby Bauer disc diffusion method was used to determine the antibiogram of isolates. Isolates were also subjected to ESBL testing using the single-disc combination method. Carbapenem-resistant isolates were identified by the Kirby Bauer disc diffusion method and then examined genotypically for the presence of blaKPC-1, blaIMP-1, blaVIM-1, blaNDM-1, and blaOXA-48 genes via polymerase chain reaction (PCR). Of the 230 isolates comprising E. coli (40.9%), Citrobacter spp. (32.6%), K. pneumoniae (9.1%), P. mirabilis (6.1%), P. vulgaris (5.2%), Enterobacter spp (3.5%)., K. oxytoca (2.2%), and Serratia marcenses (0.4%). Most isolates were from urine 162(70.4%) and wound samples. The isolates showed high resistance to ampicillin 171 (74.3%) and cefuroxime 134(58.3%). The prevalence of MDR was 35.2% (81), with E. coli 40(42.6%) being the majority that exhibited MDR. Of the 230 isolates, 113(49.1%) were ESBL producers, with E. coli 54(57.5%) accounting for the majority, while Serratia marcenses was the least. Of the 13 (5.7%) CRE isolates that showed resistance towards carbapenem in the disc diffusion method, 11 showed the presence of the blaNDM-1 gene, while all isolates showed the presence of the blaOXA-48 gene. The prevalence of carbapenem resistance and ESBL-producing Enterobacteriaceae pathogens among patients at the Cape Coast Teaching Hospital is high and alarming. Therefore, it is imperative to consider effective infection prevention and control measures should be implemented at the hospital to prevent the rapid spread of these dangerous organisms.
Sections du résumé
BACKGROUND
Carbapenem-resistant Enterobacteriaceae (CRE) and Extended-spectrum beta-lactamase (ESBL) production among Gram-negative Enterobacteriaceae is an increasing global challenge due to the high morbidity and mortality associated with their infections, especially in developing countries where there are little antibiotic treatment options. Despite these challenges, few studies in Ghana have described the burden of CRE. Therefore, this study aimed to determine the prevalence of carbapenem-resistant Enterobacteriaceae isolated from patients at the Cape Coast Teaching Hospital (CCTH) in the Central region of Ghana.
METHODOLOGY/PRINCIPAL FINDINGS
Enterobacteriaceae isolates were collected from April to July 2019 at the bacteriology unit of CCTH using a consecutive sampling method. Isolates were identified by standard microbiological techniques and confirmed using API 20E. Kirby Bauer disc diffusion method was used to determine the antibiogram of isolates. Isolates were also subjected to ESBL testing using the single-disc combination method. Carbapenem-resistant isolates were identified by the Kirby Bauer disc diffusion method and then examined genotypically for the presence of blaKPC-1, blaIMP-1, blaVIM-1, blaNDM-1, and blaOXA-48 genes via polymerase chain reaction (PCR). Of the 230 isolates comprising E. coli (40.9%), Citrobacter spp. (32.6%), K. pneumoniae (9.1%), P. mirabilis (6.1%), P. vulgaris (5.2%), Enterobacter spp (3.5%)., K. oxytoca (2.2%), and Serratia marcenses (0.4%). Most isolates were from urine 162(70.4%) and wound samples. The isolates showed high resistance to ampicillin 171 (74.3%) and cefuroxime 134(58.3%). The prevalence of MDR was 35.2% (81), with E. coli 40(42.6%) being the majority that exhibited MDR. Of the 230 isolates, 113(49.1%) were ESBL producers, with E. coli 54(57.5%) accounting for the majority, while Serratia marcenses was the least. Of the 13 (5.7%) CRE isolates that showed resistance towards carbapenem in the disc diffusion method, 11 showed the presence of the blaNDM-1 gene, while all isolates showed the presence of the blaOXA-48 gene.
CONCLUSION
The prevalence of carbapenem resistance and ESBL-producing Enterobacteriaceae pathogens among patients at the Cape Coast Teaching Hospital is high and alarming. Therefore, it is imperative to consider effective infection prevention and control measures should be implemented at the hospital to prevent the rapid spread of these dangerous organisms.
Identifiants
pubmed: 37903118
doi: 10.1371/journal.pone.0274156
pii: PONE-D-22-23415
pmc: PMC10615269
doi:
Substances chimiques
Carbapenems
0
beta-Lactamases
EC 3.5.2.6
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0274156Informations de copyright
Copyright: © 2023 Sampah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Antimicrob Agents. 2013 Oct;42(4):372-4
pubmed: 23978353
Antimicrob Agents Chemother. 2014 Aug;58(8):4275-82
pubmed: 24777095
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Apr;57(4):406-13
pubmed: 24658670
BMC Infect Dis. 2016 Jul 11;16:326
pubmed: 27400864
Antimicrob Resist Infect Control. 2018 Mar 9;7:37
pubmed: 29541448
BMC Res Notes. 2014 Sep 09;7:619
pubmed: 25201246
AIMS Public Health. 2020 Oct 16;7(4):804-815
pubmed: 33294483
Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1287-1294
pubmed: 32124106
Int J Antimicrob Agents. 2011 Jan;37(1):62-6
pubmed: 21074376
Int J Environ Res Public Health. 2012 Oct 05;9(10):3519-29
pubmed: 23202760
Clin Microbiol Infect. 2017 Apr;23(4):216-218
pubmed: 28274769
Microb Drug Resist. 2019 Dec;25(10):1449-1457
pubmed: 31237486
Ann Clin Microbiol Antimicrob. 2016 May 04;15:29
pubmed: 27145868
Int J Med Microbiol. 2013 Dec;303(8):697-700
pubmed: 24183483
J Infect Dev Ctries. 2009 May 01;3(4):295-9
pubmed: 19759493
Antimicrob Agents Chemother. 2011 Feb;55(2):934-6
pubmed: 21115785
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Trop Med Int Health. 2017 Apr;22(4):454-464
pubmed: 28072493
Am J Infect Control. 2006 Jun;34(5 Suppl 1):S20-8; discussion S64-73
pubmed: 16813978
Cleve Clin J Med. 2013 Apr;80(4):225-33
pubmed: 23547093
Antimicrob Resist Infect Control. 2013 Nov 18;2:31
pubmed: 24237856
New Microbiol. 2007 Jul;30(3):332-9
pubmed: 17802921
BMC Infect Dis. 2016 Apr 18;16:167
pubmed: 27090787
Trop Med Infect Dis. 2019 Sep 03;4(3):
pubmed: 31484298
Int J Infect Dis. 2013 Dec;17(12):e1255-8
pubmed: 24176550
BMC Res Notes. 2010 Dec 24;3:348
pubmed: 21184671
Diagn Microbiol Infect Dis. 2011 May;70(1):119-23
pubmed: 21398074
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
Clin Infect Dis. 2009 Sep 1;49(5):682-90
pubmed: 19622043
N Engl J Med. 2005 Jan 27;352(4):380-91
pubmed: 15673804
Trop Med Health. 2021 Mar 11;49(1):23
pubmed: 33691795
mBio. 2012 Nov 27;3(6):
pubmed: 23188508
Urol Ann. 2013 Oct;5(4):313-4
pubmed: 24311922
S Afr Med J. 2012 May 10;102(7):599-601
pubmed: 22748433
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Clin Infect Dis. 2014 Oct 15;59(8):1113-22
pubmed: 25048853
Antibiotics (Basel). 2022 Dec 13;11(12):
pubmed: 36551465
Am J Trop Med Hyg. 2016 Dec 7;95(6):1277-1283
pubmed: 27799637
Int J Antimicrob Agents. 2012 Sep;40(3):282-4
pubmed: 22817914
PLoS One. 2014 Mar 21;9(3):e92323
pubmed: 24658124
Microb Genom. 2018 Jul;4(7):
pubmed: 30035710
BMC Infect Dis. 2016 Oct 24;16(1):598
pubmed: 27776490
Antimicrob Agents Chemother. 2015 Jan;59(1):682-5
pubmed: 25331700
Saudi J Biol Sci. 2015 Jan;22(1):90-101
pubmed: 25561890
Biomed Res Int. 2014;2014:303104
pubmed: 24707481
East Afr J Public Health. 2010 Sep;7(3):229-32
pubmed: 21516960
Urol Ann. 2013 Oct;5(4):312-3
pubmed: 24311921
Ann Clin Microbiol Antimicrob. 2013 Oct 12;12:28
pubmed: 24119299
Front Microbiol. 2021 Oct 06;12:740348
pubmed: 34690985
J Trop Med. 2020 Apr 30;2020:6167234
pubmed: 32411256
J Clin Microbiol. 2005 Feb;43(2):745-9
pubmed: 15695674
BMC Res Notes. 2018 Aug 31;11(1):629
pubmed: 30170613